• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of (2S)-2-(ethylamino)-3-methylbutanoic acid (CAS: 90600-06-9)

The compound (2S)-2-(ethylamino)-3-methylbutanoic acid (CAS: 90600-06-9) has garnered significant attention in recent years due to its potential applications in the chemical, biological, and pharmaceutical fields. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. The information presented here is based on a thorough review of recent academic literature, industry reports, and technical documents.

Recent studies have highlighted the unique structural and functional properties of (2S)-2-(ethylamino)-3-methylbutanoic acid. The compound is a chiral amino acid derivative, which makes it particularly interesting for applications in asymmetric synthesis and drug development. Researchers have explored its role as a building block for more complex molecules, as well as its potential as a bioactive compound. The stereochemistry at the 2-position is critical for its biological activity, and recent synthetic methodologies have focused on optimizing the enantioselective synthesis of this compound.

One of the key areas of investigation has been the pharmacological potential of (2S)-2-(ethylamino)-3-methylbutanoic acid. Preliminary studies suggest that it may exhibit neuroprotective effects, making it a candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. In vitro and in vivo experiments have demonstrated its ability to modulate neurotransmitter systems, although the exact mechanisms remain under investigation. These findings are particularly promising given the growing need for novel therapeutic agents in neurology.

In addition to its neurological applications, (2S)-2-(ethylamino)-3-methylbutanoic acid has also been studied for its potential in metabolic disorders. Recent research indicates that it may influence amino acid metabolism and energy homeostasis, which could have implications for conditions such as diabetes and obesity. The compound's ability to interact with key metabolic enzymes and pathways has been a focal point of these studies, with some researchers proposing it as a lead compound for further drug development.

The synthesis of (2S)-2-(ethylamino)-3-methylbutanoic acid has also seen significant advancements. New catalytic methods have been developed to improve yield and enantioselectivity, addressing some of the challenges associated with its production. These innovations are not only important for scaling up production but also for ensuring the compound's purity and consistency, which are critical for pharmaceutical applications. Recent patents and technical reports highlight the industrial interest in optimizing these synthetic routes.

Despite these promising developments, several challenges remain. The bioavailability and pharmacokinetics of (2S)-2-(ethylamino)-3-methylbutanoic acid need further exploration to determine its suitability as a drug candidate. Additionally, more comprehensive toxicological studies are required to assess its safety profile. Researchers are also investigating potential synergies with other compounds to enhance its therapeutic efficacy. These ongoing studies will be crucial for translating laboratory findings into clinical applications.

In conclusion, (2S)-2-(ethylamino)-3-methylbutanoic acid (CAS: 90600-06-9) represents a compound of significant interest in the chemical, biological, and pharmaceutical fields. Its unique properties and potential therapeutic applications make it a promising candidate for further research and development. The latest studies underscore its versatility and highlight the need for continued investigation to fully realize its potential. This research brief serves as a snapshot of the current state of knowledge and aims to stimulate further discussion and exploration in this area.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)